Biotechnology

Relay Therapeutics, Inc. stock analysis: $117M cash burn, $10M revenue and a two-year high. See what the Quality, Growth and Opportunity scores show.

Parabilis Medicines, Inc. stock analysis: a $3.37B pre-revenue biotech with strong liquidity, deep losses and no model signal. See the risks.

Legend Biotech stock analysis: revenue up 51.9% and a Growth score of 93, but a net loss and thin cash flow keep our scoring model at Hold.

Recursion Pharmaceuticals stock analysis: $197M of cash burned in six months and 28% more shares. Why the model rates RXRX a Sell before its November data.

BeOne Medicines stock analysis: Brukinsa drove 29.6% revenue growth and strong margins, but a 64.06 P/E keeps the model’s signal at Hold.

Incyte stock analysis: INCY grows revenue 37.7% at a 15.46 P/E with a 98/100 Quality score. Why the model rates it a Buy despite the 2028 Jakafi cliff.

Faeth Therapeutics stock analysis: a pre-revenue clinical biotech trading near its two-year high, with no debt, steep losses and a model rating of N/A.